Epic Sciences Appoints Dave Henderson as Chief Information Officer
26 August 2015
Epic Sciences, Inc. (“Epic Sciences”), announced today the appointment of Dave Henderson as Epic Sciences’ chief information officer (CIO). Mr. Henderson has more than 20 years of experience in information technologies at companies including Sequenom, Inc., CBS Corporation, and Paramount Pictures Corporation.
New CEO and $80M Later, Syndax Looks Prepped for Second IPO Try
24 August 2015
If Syndax Pharmaceuticals’ latest financing is any indication, the Waltham, MA-based firm looks to have another shot at an initial public offering in mind.
24 August 2015
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the safety, tolerability and preliminary efficacy of Syndax's entinostat, an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with Genentech's atezolizumab (MPDL3280A), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1), in patients with triple-negative breast cancer.
Syndax Raises $80 Million In Series C Financing
24 August 2015
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications, announced today that it has completed an $80 millionSeries C financing. The financing was led by Fidelity Management & Research Company and Delos Capital Fund LP with participation from EcoR1 Capital, OrbiMed, Jennison Associates (on behalf of certain clients), Tavistock Life Sciences, Arrowpoint Partners, Cormorant Asset Management, BioMed Ventures and undisclosed top-tier mutual funds, as well as existing investors Domain Associates, MPM Capital, RusnanoMedInvest (RMI) and Forward Ventures.
18 August 2015
Today, MIT Technology Review revealed its annual list of Innovators Under 35. For over a decade, the global media company has recognized a list of exceptionally talented technologists whose work has great potential to transform the world. For her work in the field of biotechnology and medicine, Epic Sciences' Dena Marrinucci, Ph.D., has been recognized as an entrepreneur on the list for her groundbreaking work in developing and advancing a new technology to unlock the promise of using a simple blood test, called a liquid biopsy, to manage cancer treatments.
11 August 2015
Epic Sciences announced today the publication of its research in the Journal of Circulating Biomarkers validating the company's no cell left behind™ platform. The data published demonstrate reproducible and linear assay performance in CTC enumeration as well as additional utility in downstream molecular characterization of single CTCs, including protein biomarker analysis and single cell genomics.
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2015 Financial Results
04 August 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for the second quarter ended June 30, 2015.
30 July 2015
Miramar® Labs, a global aesthetics company, today announced the release of the Optimized Treatment Protocol (OTP) in Europe and the Middle East. The new protocol, designed to increase patient satisfaction and reduce treatment times, should further expand the potential patient population for the miraDry® System which eliminates underarm sweat and odor glands.
23 July 2015
Miramar® Labs, an innovative global aesthetic company, announced today its miraDry® System received clearance from the U.S. Food & Drug Administration (FDA) for the treatment of unwanted underarm hair, and permanent reduction of underarm hair of all colors. This announcement establishes miraDry as the only technology FDA cleared for the treatment of underarm hair of all colors as well as the permanent reduction of underarm sweat.
Miramar Labs® Announces Global Expansion of miraDry® System into Chinese Market
16 July 2015
Global aesthetic company Miramar® Labs, Inc., announced today that it has received State Food & Drug Administration (SFDA) approval for the marketing and sale of the miraDry® system in the People's Republic of China. The approval follows US Food and Drug Administration (FDA) clearance of miraDry in January 2011and (CE) Mark approval in December 2013.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024